Bioceres Crop Solutions Statistics
Total Valuation
BIOX has a market cap or net worth of $185.00 million. The enterprise value is $418.96 million.
Important Dates
The next estimated earnings date is Monday, September 8, 2025, after market close.
| Earnings Date | Sep 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOX has 62.71 million shares outstanding. The number of shares has decreased by -4.77% in one year.
| Current Share Class | 62.71M |
| Shares Outstanding | 62.71M |
| Shares Change (YoY) | -4.77% |
| Shares Change (QoQ) | -0.61% |
| Owned by Insiders (%) | 1.96% |
| Owned by Institutions (%) | 15.80% |
| Float | 31.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 31.05 |
| PS Ratio | 0.48 |
| Forward PS | 0.45 |
| PB Ratio | 0.60 |
| P/TBV Ratio | 12.79 |
| P/FCF Ratio | 4.72 |
| P/OCF Ratio | 3.99 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 10.25, with an EV/FCF ratio of 10.70.
| EV / Earnings | n/a |
| EV / Sales | 1.09 |
| EV / EBITDA | 10.25 |
| EV / EBIT | 18.79 |
| EV / FCF | 10.70 |
Financial Position
The company has a current ratio of 1.02, with a Debt / Equity ratio of 0.79.
| Current Ratio | 1.02 |
| Quick Ratio | 0.72 |
| Debt / Equity | 0.79 |
| Debt / EBITDA | 5.99 |
| Debt / FCF | 6.98 |
| Interest Coverage | 0.87 |
Financial Efficiency
Return on equity (ROE) is -2.67% and return on invested capital (ROIC) is 2.28%.
| Return on Equity (ROE) | -2.67% |
| Return on Assets (ROA) | 1.70% |
| Return on Invested Capital (ROIC) | 2.28% |
| Return on Capital Employed (ROCE) | 4.78% |
| Revenue Per Employee | $985,320 |
| Profits Per Employee | -$23,291 |
| Employee Count | 389 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 2.08 |
Taxes
| Income Tax | -9.50M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.71% in the last 52 weeks. The beta is 0.44, so BIOX's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | -70.71% |
| 50-Day Moving Average | 4.07 |
| 200-Day Moving Average | 5.15 |
| Relative Strength Index (RSI) | 25.95 |
| Average Volume (20 Days) | 155,245 |
Short Selling Information
| Short Interest | 489,542 |
| Short Previous Month | 509,534 |
| Short % of Shares Out | 0.78% |
| Short % of Float | 1.54% |
| Short Ratio (days to cover) | 3.80 |
Income Statement
In the last 12 months, BIOX had revenue of $383.29 million and -$9.06 million in losses. Loss per share was -$0.14.
| Revenue | 383.29M |
| Gross Profit | 149.83M |
| Operating Income | 22.29M |
| Pretax Income | 9.30M |
| Net Income | -9.06M |
| EBITDA | 40.87M |
| EBIT | 22.29M |
| Loss Per Share | -$0.14 |
Full Income StatementBalance Sheet
The company has $39.35 million in cash and $273.30 million in debt, giving a net cash position of -$233.96 million or -$3.73 per share.
| Cash & Cash Equivalents | 39.35M |
| Total Debt | 273.30M |
| Net Cash | -233.96M |
| Net Cash Per Share | -$3.73 |
| Equity (Book Value) | 344.98M |
| Book Value Per Share | 4.92 |
| Working Capital | 5.90M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $46.39 million and capital expenditures -$7.23 million, giving a free cash flow of $39.17 million.
| Operating Cash Flow | 46.39M |
| Capital Expenditures | -7.23M |
| Free Cash Flow | 39.17M |
| FCF Per Share | $0.62 |
Full Cash Flow StatementMargins
Gross margin is 39.09%, with operating and profit margins of 5.82% and -2.36%.
| Gross Margin | 39.09% |
| Operating Margin | 5.82% |
| Pretax Margin | -4.90% |
| Profit Margin | -2.36% |
| EBITDA Margin | 10.66% |
| EBIT Margin | 5.82% |
| FCF Margin | 10.22% |
Dividends & Yields
BIOX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.77% |
| Shareholder Yield | 4.77% |
| Earnings Yield | -4.90% |
| FCF Yield | 21.17% |
Analyst Forecast
The average price target for BIOX is $8.38, which is 184.07% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.38 |
| Price Target Difference | 184.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 6.16% |
| EPS Growth Forecast (5Y) | 64.43% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BIOX has an Altman Z-Score of 1.26 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.26 |
| Piotroski F-Score | 5 |
